GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022
ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will present at the World Vaccine & Immunotherapy Congress (WVIC) West Coast 2022, taking place November 28-December 1, 2022, in San Diego, California.
- ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will present at the World Vaccine & Immunotherapy Congress (WVIC) West Coast 2022, taking place November 28-December 1, 2022, in San Diego, California.
- He will also discuss GeoVaxs COVID-19 vaccine, GEO-CM04S1, which is currently in two Phase 2 clinical trials, one as a more potent primary vaccine for immunocompromised patients and the other trial as a booster vaccine for healthy patients who have previously received an mRNA vaccine.
- GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the worlds most threatening infectious diseases.
- GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.